Clinical trials located in


Greifswald city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Greifswald, located in northeastern Germany, is a city steeped in history and academia. Founded in the 13th century, it is home to one of the oldest universities in Germany, the University of Greifswald, established in 1456. This city, nestled by the Baltic Sea, boasts a well-preserved medieval town center, with the majestic St. Nikolai Cathedral as a standout landmark. Greifswald’s connection to the famous Romantic painter Caspar David Friedrich enriches its cultural heritage, with various sites around the city having inspired his works. Additionally, the city is a gateway to the scenic islands of Rügen and Usedom.

  • CT-EU-00114975

    Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

  • Treating post-COVID heart issues with Prednisolone and Losartan

    This study looks at heart problems caused by Covid-19. Sometimes people who have had the virus continue to experience symptoms after they recover. This is called “long COVID.” One of the symptoms is heart problems. The heart is an important organ with high oxygen requirements and may be damaged in “long Covid-19”. These heart problems can cause shortness of breath, chest pain and palpitations. In the study, researchers will look at the use of two drugs – losartan and prednisolone – to treat these symptoms. People who have had Covid-19 and have such symptoms can take part in the research. Patients will receive medication or a placebo for 16 weeks. Scientists will track changes in heart function and symptoms to see if the treatment is working.

  • Evaluating acalabrutinib efficacy in elderly diffuse large B cell lymphoma patients

    This clinical trial is set up to check a new treatment for older adults suffering from a specific type of blood cancer called diffuse large B-cell lymphoma (DLBCL). The new treatment includes a medicine named acalabrutinib added to the standard treatment currently known as R-miniCHOP. The key aim of this trial is to see if acalabrutinib can help patients live longer without their cancer getting worse. Participants will be split randomly into two groups. One group will receive the standard treatment and the other will get the standard treatment plus acalabrutinib. Progress of the disease will be checked and noted until the end of study.

  • Studying rimegepant’s effectiveness on Migraine

    This study is testing a new treatment, rimegepant, for adults with migraines who cannot take traditional migraine medications, such as triptans, possibly due to reasons like having a heart condition. The research aims to evaluate the effectiveness and tolerability of rimegepant over a 12-week period. Participants will be asked to rate their headache pain on a scale ranging from 0 (no pain) to 3 (severe pain) as one of the methods to assess the treatment’s impact.

    AustriaBelgiumDenmarkFinlandFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Comparing atogepant and topiramate for migraine prevention

    In this study, a comparison is being made between two different medicines aimed at preventing migraines in adults. Migraines manifest as severe headaches on one side of the head, accompanied by symptoms such as nausea, throbbing pain, or sensitivity to light and sound. The two medicines under comparison are named atogepant and topiramate. Atogepant is currently employed for migraine prevention in individuals experiencing migraines from 0 to 14 days per month, and the study seeks to evaluate its potential broader application. Topiramate is already widely utilized for migraine prevention. Participants in this study will be divided into two groups: one group will be administered atogepant, while the other will receive topiramate for a duration of 24 weeks. Following this period, those eligible to continue will all receive atogepant for an additional 52 weeks. The study will assess their progress and monitor any potential side effects.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyPolandPortugalUnited Kingdom
  • Studying Ianalumab efficacy in primary immune thrombocytopenia

    This study is testing a drug called Ianalumab along with another drug called Eltrombopag to help people with a blood disease called primary immune thrombocytopenia, or ITP. ITP causes the body to destroy its platelets, which are needed to help the blood clot. Some people with ITP do not respond well to regular steroid treatment, so this study will test whether adding Ianalumab to Eltrombopag may help them more. Participants receive varying doses of Ianalumab or placebo along with Eltrombopag, with the goal of increasing the time to treatment failure. The careful design of the study ensures precise evaluation of this potential new therapy, providing hope for improved treatment of ITP.

    AustriaBelgiumCzechiaGermanyHungaryItalyNetherlandsNorwayRomaniaSpainUnited Kingdom
  • Testing new therapy in treating Sudden Sensorineural Hearing Loss

    The testing of a new drug, AC102, is underway in this study for individuals experiencing sudden, unexplained hearing loss, known as Idiopathic Sudden Sensorineural Hearing Loss. The study aims to compare the effectiveness of AC102 with the standard treatment, which involves oral steroid intake. Each patient will receive a single injection of AC102 into the eardrum. The study will evaluate the safety of AC102 and assess the improvement in hearing. After 28 days, the changes in hearing will be measured by testing the understanding of different sound levels.

  • Testing the efficacy of teclistamab vs other drugs for relapsed or refractory multiple myeloma treatment

    The study is evaluating a treatment for a blood cancer known as multiple myeloma. Two different treatments are being compared to assess their effectiveness in both slowing down the disease and minimizing side effects. The first treatment involves a single medicine called teclistamab, while the second offers a choice between two combinations of multiple medicines (either PVd – pomalidomide, bortezomib, dexamethasone or Kd – carfilzomib, dexamethasone). Both treatments have been previously administered to individuals with similar conditions. Individuals who have undergone prior treatment, including the use of an anti-CD38 monoclonal antibody and lenalidomide, but experienced a recurrence or lack of resolution of the disease, are eligible to participate in this study. The objective is to determine the duration it takes for the disease to progress under different treatments. Additionally, the study will monitor changes in health and potential medication-related issues through regular check-ups.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Thrombolysis therapy in treating acute Pulmonary Embolism

    This study aims to evaluate a reduced dose of thrombolytic treatment for patients with intermediate-high-risk acute pulmonary embolism. It compares the new treatment approach with a placebo to assess effectiveness and safety. The study’s focus is on reducing the risk of major and intracranial bleeding associated with full-dose thrombolytic treatment. Participants will receive either the experimental treatment or a placebo, alongside standard anticoagulation therapy. The primary goal is to determine the efficacy and safety of the reduced dosage at day 30, with long-term follow-up assessments planned. This research is crucial for improving treatment options for patients with this serious lung condition.

  • Study on Ianalumab’s effect on primary immune phrombocytopenia

    This trial is testing Ianalumab against a placebo in patients with a condition called primary immune thrombocytopenia (ITP), a disorder where the body’s immune system mistakenly targets and destroys its own platelets – blood cells that help with clotting and prevent bleeding. The study aims at finding if two different doses of Ianalumab in combination with first-line corticosteroids can efficiently keep the platelet count above a certain level (30 G/L). The study is happening at many different locations and is random and blind, which means neither patients nor doctors know who gets which treatment, to ensure fairness and unbiased results.

    AustriaBelgiumBulgariaCzechiaFranceGermanyHungaryItalyNorwayRomaniaSpainUnited Kingdom
  • Comparing new drug-Cytarabine Danuorubicin with standard chemotheraphy in adults with Acute Myeloid Leukemia

    This study is comparing two types of strong medicine, or ‘chemotherapy’, used to treat a disease called Acute Myeloid Leukemia (AML). This disease can sometimes be harder to treat in some patients due to their genetics. In this study, some people will get the usual strong medicine, and some people will get a new type of strong medicine called CPX-351 (Cytarabine and Danuorubicin). The researchers will also look at who might get fully or almost fully better from the disease.This trial is investigating how a new kind of very strong drug, CPX-351, might work compared to the usual strong drug treatment for a blood cancer called Acute Myeloid Leukemia (AML). These drugs are used when someone has recently found out they have AML, and their body has certain genetic markers making it harder for usual treatments to work. This trial is also looking at different degrees of recovery. The treatments may work differently based on people’s genes.

  • Examining new dosing of belantamab for resistant multiple myeloma

    The study is called DREAMM-14 and is intended for people with a disease called multiple myeloma that does not respond to other treatments. Scientists are investigating various possible uses of a drug called belantamab mafodotin. They want to see if changing the dose of the drug or the frequency of its administration can fight the disease more effectively and cause fewer side effects. They will also look at changes in your vision and the condition of the cornea (the clear front part of the eye) on a scale of 0 to 4. This scale assesses the condition of the cornea and any changes in vision, with 0 being no change and 4 being a major change. Doctors will measure how many people experience corneal changes, how long they last, and whether the events are related to the amount of medication they take. They will also look at how the disease responds to the medicine and how long it takes to take treatment.

    FranceGermanyGreeceItalyPolandSpainUnited Kingdom
  • Study on volrustomig’s impact on advanced head & neck cancer after chemoradiation

    This clinical study explores a new treatment option, volrustomig, for patients with a specific type of head and neck cancer known as unresected locally advanced head and neck squamous cell carcinoma. The study compares volrustomig with standard observation in patients who have undergone chemoradiotherapy but whose cancer has not progressed. The trial aims to enroll over a thousand participants and focuses on evaluating how well the treatment controls cancer progression and impacts patients’ survival and quality of life. The trial is open to a specific group of patients with certain criteria and is conducted across multiple locations.

    AustriaBelgiumFranceGermanyHungarySpainUnited Kingdom
  • Studying the safety and effectiveness of a UV1 vaccine combination as an addition to standard treatment in head and neck cancer

    This clinical study explores a new vaccine, UV1, for patients with a specific type of head and neck cancer that has returned or spread. Participants will receive UV1 alongside the standard medication, pembrolizumab, to see if this combination can improve survival and shrink the cancer more effectively than the standard treatment alone. This study will also assess how long the benefits last, how the body’s immune system responds, and monitor the cancer through blood tests. The treatment involves regular injections over 13 weeks, with close tracking of any side effects and the cancer’s response to the therapy. The study aims to find a more effective first-line treatment with acceptable side effects for patients who might be too weak for chemotherapy.

  • Myeloma study: lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab

    A groundbreaking study for newly diagnosed multiple myeloma patients is assessing whether a subcutaneous form of the drug isatuximab is as effective as the intravenous version. This study combines isatuximab with three other medications, lenalidomide, dexamethasone and bortezomib, in an approach known as induction therapy. The goal is to enhance patient comfort and maintain treatment effectiveness, potentially leading to an excellent partial response or better in patients eligible for stem cell transplants.

  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

  • Alteplase low-dose trial for acute pulmonary embolism care

    In this trial, participants with a specific type of lung clot called intermediate-high-risk acute pulmonary embolism are given a lower dose of Alteplase, a medication that dissolves blood clots. The study compares the effects of this reduced dose to a non-active placebo to see if it can reduce clot-related risks without increasing bleeding, especially in the brain. The treatment involves a short intravenous injection and is tested alongside standard anticoagulants. Success is measured by patient health 30 days after the treatment, with an eye on long-term outcomes like survival and heart function up to two years later.


See more clinical trials in other cities in Germany: